Rapid assessment of antiviral activity and cytotoxicity of silver nanoparticles using a novel application of the tetrazolium-based colorimetric assay

Journal of Virological Methods

Volumn 183, Issue 1, 2012, Pages 19-24

  Trefry, John C ^a,c   Wooley, Dawn P ^b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Antiviral agents; Inhibitory concentration 50; Metal nanoparticles; Silver; Tetrazolium salts

Indexed keywords

SILVER NANOPARTICLE; TETRAZOLIUM;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEK293; COLONY FORMING UNIT; COLORIMETRY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; COLORIMETRY; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; SILVER; STAINING AND LABELING; TETRAZOLIUM SALTS; THIAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84860569459     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2012.03.014     Document Type: Article

References (38)

1. Bernas T., Dobrucki J. Mitochondrial and nonmitochondrial reduction of MTT: interaction of MTT with TMRE, JC-1, and NAO mitochondrial fluorescent probes. Cytometry 2002, 47:236-242.
2. Berridge M.V., Herst P.M., Tan A.S. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol. Annu. Rev. 2005, 11:127-152.
3. Bradley D.E. A study of the negative staining process. J. Gen. Microbiol. 1962, 29:503-516.
4. Brunauer S., Emmett P.H., Teller E. Adsorption of gases in multimolecular layers. J. Am. Chem. Soc. 1938, 60:309-319.
5. Cronin J., Zhang X.Y., Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther. 2005, 5:387-398.
6. da Costa A.O., de Assis M.C., Marques Ede A., Plotkowski M.C. Comparative analysis of three methods to assess viability of mammalian cells in culture. Biocell 1999, 23:65-72.
7. Dini L., Panzarini E., Serra A., Buccolieri A., Manno D. Synthesis and in vitro cytotoxicity of glycans-capped silver nanoparticles. Nanomater. Nanotechnol. 2011, 1:58-63.
8. DiStefano D.J., Gould S.L., Munshi S., Robinson D.K. Titration of human-bovine rotavirus reassortants using a tetrazolium-based colorimetric end-point dilution assay. J. Virol. Methods 1995, 55:199-208.
9. El Badawy A.M., Luxton T.P., Silva R.G., Scheckel K.G., Suidan M.T., Tolaymat T.M. Impact of environmental conditions (pH ionic strength, and electrolyte type) on the surface charge and aggregation of silver nanoparticles suspensions. Environ. Sci. Technol. 2010, 44:1260-1266.
10. Elechiguerra J.L., Burt J.L., Morones J.R., Camacho-Bragado A., Gao X., Lara H.H., Yacaman M.J. Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnol. 2005, 3:6.
11. Evanoff D.D., Chumanov G. Synthesis and optical properties of silver nanoparticles and arrays. Chemphyschem 2005, 6:1221-1231.
12. Heldt C.L., Hernandez R., Mudiganti U., Gurgel P.V., Brown D.T., Carbonell R.G. A colorimetric assay for viral agents that produce cytopathic effects. J. Virol. Methods 2006, 135:56-65.
13. Huang K.J., Wooley D.P. A new cell-based assay for measuring the forward mutation rate of HIV-1. J. Virol. Methods 2005, 124:95-104.
14. Huang K.T., Chen Y.H., Walker A.M. Inaccuracies in MTS assays: major distorting effects of medium, serum albumin, and fatty acids. Biotechniques 2004, 37. 406, 408, 410-402.
15. Karber G. Contribution to the collective treatment of pharmacological serial experiments [German]. Arch. Pathol. Pharmacol. 1931, 480-483.
16. Kawata K., Osawa M., Okabe S. In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells. Environ. Sci. Technol. 2009, 43:6046-6051.
17. Kim V.N., Mitrophanous K., Kingsman S.M., Kingsman A.J. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 1998, 72:811-816.
18. Lara H.H., Ayala-Nunez N.V., Ixtepan-Turrent L., Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J. Nanobiotechnol. 2010, 8:1.
19. Lara H.H., Garza-Trevino E.N., Ixtepan-Turrent L., Singh D.K. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. J. Nanobiotechnol. 2011, 9:30.
20. Lara H.H., Ixtepan-Turrent L., Garza-Trevino E.N., Rodriguez-Padilla C. PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J. Nanobiotechnol. 2010, 8:15.
21. Lara H.H., Ixtepan-Turrent L., Garza Trevino E.N., Singh D.K. Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins. J. Nanobiotechnol. 2011, 9:38.
22. Liu Y., Peterson D.A., Kimura H., Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J. Neurochem. 1997, 69:581-593.
23. Lu L., Sun R.W., Chen R., Hui C.K., Ho C.M., Luk J.M., Lau G.K., Che C.M. Silver nanoparticles inhibit hepatitis B virus replication. Antivir. Ther. 2008, 13:253-262.
24. Lu X., Rycenga M., Skrabalak S.E., Wiley B., Xia Y. Chemical synthesis of novel plasmonic nanoparticles. Annu. Rev. Phys. Chem. 2009, 60:167-192.
25. Mehrbod P., Motamed N., Tabatabaian M., Soleimani E.R., Amini E., Shahidi M., Kheiri M.T. In vitro antiviral effect of nanosilver on Influenza virus. Arch. SID 2009, 17:88-93.
26. Monteiro-Riviere N.A., Inman A.O., Zhang L.W. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol. Appl. Pharmacol. 2009, 234:222-235.
27. Morones J.R., Frey W. Environmentally sensitive silver nanoparticles of controlled size synthesized with PNIPAM as a nucleating and capping agent. Langmuir 2007, 23:8180-8186.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
29. Pabbruwe M.B., Stewart K., Chaudhuri J.B. A comparison of colorimetric and DNA quantification assays for the assessment of meniscal fibrochondrocyte proliferation in microcarrier culture. Biotechnol. Lett. 2005, 27:1451-1455.
30. Patel M.I., Tuckerman R., Dong Q. A Pitfall of the 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay due to evaporation in wells on the edge of a 96 well plate. Biotechnol. Lett. 2005, 27:805-808.
31. Seiler A.E., Buesen R., Visan A., Spielmann H. Use of murine embryonic stem cells in embryotoxicity assays: the embryonic stem cell test. Methods Mol. Biol. 2006, 329:371-395.
32. Stein B.S., Gowda S.D., Lifson J.D., Penhallow R.C., Bensch K.G., Engleman E.G. pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 1987, 49:659-668.
33. Sun R.W.-Y., Chen R., Chung N.P.-Y., Ho C.-M., Lin C.-L.S., Che C.-M. Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem. Commun. 2005, 2005:5059-5061.
34. Trefry J.C., Monahan J.L., Weaver K.M., Meyerhoefer A.J., Markopolous M.M., Arnold Z.S., Wooley D.P., Pavel I.E. Size selection and concentration of silver nanoparticles by tangential flow ultrafiltration for SERS-based biosensors. J. Am. Chem. Soc. 2010, 132:10970-10972.
35. Xiang D.X., Chen Q., Pang L., Zheng C.L. Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro. J. Virol. Methods 2011, 178:137-142.
36. Yonezawa A., Cavrois M., Greene W.C. Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J. Virol. 2005, 79:918-926.
37. Zhao F., Zhao Y., Liu Y., Chang X., Chen C. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 2011, 7:1322-1337.
38. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 1998, 72:9873-9880.